RxDoctor Payments Data

Gregg Zernich, DO

Family Medicine · Monaca, PANPI 1558387308

Payments from drug & device makers

$17,429in general payments, 2019–2025

Across 1,156 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • Pfizer$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Amgen$731
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$17,34299%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk229$3,227
AbbVie(2 entities)131$1,982
Pfizer123$1,308
GSK82$1,308
Lilly USA, LLC68$1,141
Amgen65$731
E.r. Squibb & Sons, L.L.C.50$729
Boehringer Ingelheim46$660
Johnson & Johnson(2 entities)38$613
AstraZeneca(2 entities)35$611
Merck24$407
Astellas Pharma US Inc17$396
Abbott19$388
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$291
Bayer18$286
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$286
Kowa Pharmaceuticals America, Inc.20$286
Amarin Pharma, Inc.21$255
Idorsia Pharmaceuticals US Inc8$144
Sumitomo Pharma America, Inc.7$142
Novartis9$141
Currax Pharmaceuticals LLC9$137
Phathom Pharmaceuticals, Inc.7$132
Vanda Pharmaceuticals Inc.5$130
Sanofi-aventis U.S. LLC8$119
Lundbeck LLC7$116
Biohaven Pharmaceutical Holding Company Ltd.6$106
Biohaven Pharmaceuticals, Inc.6$88
Viatris Specialty LLC4$76
Arbor Pharmaceuticals, Inc.1$75
Alkermes, Inc.2$71
Edwards Lifesciences3$69
Axsome Therapeutics, Inc.3$65
Harmony Biosciences LLC2$55
Sunovion Pharmaceuticals Inc.4$50
Antares Pharma, Inc.3$49
Daiichi Sankyo Inc.3$48
Ironwood Pharmaceuticals, Inc3$48
Circassia Inc.3$47
Esperion Therapeutics, Inc.2$46
Dexcom, Inc.3$43
Ardelyx, Inc.2$36
Otsuka America Pharmaceutical, Inc.2$36
Teva Pharmaceuticals USA, Inc.2$34
Amphastar Pharmaceuticals, Inc.2$33
Sanofi Pasteur Inc.1$31
Regeneron Healthcare Solutions, Inc.2$27
Valinor Pharma, LLC1$24
Biodelivery Sciences International, Inc.2$22
Heartflow, Inc.1$22
Takeda Pharmaceuticals U.S.A., Inc.2$22
Inspire Medical Systems, Inc.1$21
Boston Scientific1$20
Theracosbio, LLC1$19
Medtronic1$19
Gilead1$18
Collegium Pharmaceutical, Inc.1$18
Amneal Pharmaceuticals LLC1$17
Vivus LLC1$17
Paratek Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,429 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,589
Medicare patients
312
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$208,305
OzempicSemaglutide182$207,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter208$156,450
XareltoRivaroxaban130$95,756
JardianceEmpagliflozin80$86,413
TrulicityDulaglutide73$70,653
RelistorMethylnaltrexone Bromide12$55,193
MounjaroTirzepatide45$53,959
SynjardyEmpagliflozin/Metformin Hcl43$44,215
OxycontinOxycodone Hcl34$44,098
MyrbetriqMirabegron59$38,454
ProliaDenosumab19$33,420
FarxigaDapagliflozin Propanediol24$32,615
Synjardy XrEmpagliflozin/Metformin Hcl40$30,347
LinzessLinaclotide33$26,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$3,227$228,641199 claims
PfizerEliquis, Premarin$1,308$213,939292 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Spiriva Respimat, Jentadueto$660$190,889211 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,308$179,792250 claims
Lilly USA, LLCTrulicity, Mounjaro$1,141$124,612118 claims
Johnson & JohnsonXarelto$613$95,756130 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$291$55,19312 claims
AbbVieLinzess, Vraylar, Synthroid$1,982$50,316156 claims
Astellas Pharma US IncMyrbetriq$396$38,45459 claims
AmgenProlia$731$33,42019 claims
AstraZenecaFarxiga$611$32,61524 claims
NovartisEntresto$141$26,11624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Monaca

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →